Advertisement
Advertisement

The Use of Calcaneal Stiffness Index to Screen for Osteoporosis in HIV-Infected Individuals

May/June 2011

Chelsea and Westminster Hospital reported results on the feasibility of using calcaneal stiffness as an indicator for osteoporosis in HIV-positive patients.1

Currently, a DEXA scan remains the gold standard measure of Bone Mineral Density (BMD) with a T-score of -1 and above being normal -1 to -2.5 indicating osteopaenia and <-2.5 indicating osteoperosis. However, DEXA scans are not available in all clinics, require extra patient attendance and radiation safety approval and cost around £60.

Several studies have previously shown a significant difference in BMD and fracture prevalence in both HIV-positive men and women. A population-based study by Triant et al. reported a high level of significance (p=0.0001 in men and p=0.002 in women) in bone fractures between over 2,200,000 HIV-negative patients and 8,525 HIV-positive patients.2

Advertisement
Scourfield et al at Chelsea and Westminster Hospital have found that a calcaneal ultrasound test using the GE-Achilles Insight machine is able to calculate the calcaneal stiffness index (CSI) and estimate the t-score. In HIV-negative people, CSI is currently used to predict hip fracture risk and vertebral fracture in post-menopausal women. However, this is not yet used in HIV-positive people.

The test is portable, takes 15 seconds to perform with minimal inter-operator variability. Osteopenia is most readily apparent in parts of the skeleton with high bone turnover as found in highly trabeculated, weight-bearing bones. The calcaneus (heel bone) is ideal as it is easily accessible, comfortable for the patient and weight-bearing.

The study aimed to correlate CSI with DEXA scan results in an HIV-positive population to assess the value and cost-effectiveness of using the GE-Achilles Insight machine as a screen tool for osteoperosis.

CSI measurements using the GE-Achilles Insight were performed on 100 people at random who had undergone a DEXA scan within the last 6 months. Their median age was 51 years (IRQ: 46-58), 85% were male, positive for a median of 15 years (IQR: 11-20) and with a BMI of 24 (IQR 21-26). Ethnicity of participants was 83% white Caucasian, 10% black African, 4% SE Asian, 1% black Caribbean, 1% Middle Eastern and 1% Indian. CSI scores were analysed to determine the optimum sensitivity. A cost-effectiveness analysis was then conducted.

The DEXA scan showed a prevalence of 15% osteoporosis and 55% osteopaenia. The CSI t-score showed 67% positive (estimated t-score =<-1.0) and 43% negative (estimated t-score >-1.0). This meant in the CSI t-score had 100% sensitivity but only 51% specificity compared to the DEXA scan. The positive predictive value of a CSI score of =<-2.5 for osteoporosis was 30%.

The cost-effectiveness analysis concluded that CSI is reliable and cost-effective method. If the 100 study participants involved in this study who had all previously undergone the DEXA scan had been screened first with CSI using a cut-off value of =<-1.0 this would have resulted in all cases of osteoporosis identified and 43 fewer DEXA scans which amounts to a saving of £2,795 (at an average cost of £65 per scan). However, due to the lower level of specificity, this would also have meant that 19 cases of oesteopenia were missed.


Comment

The cost of the GE-Achilles Insight is only £12,000 and for a minimal investment the considerable ongoing concerns of high levels of currently undiagnosed bone disease could be easily addressed in every large clinic.

EACS guidelines recommend repeat DEXA screening every 3-5 years in patients at higher risk of BMD and include HIV as a risk factor when using the FRAX calculator and age over 50 years as a risk factor if not using FRAX. The financial and health saving appear significant given aging positive population.

CSI t-scores are also quicker, easier and less inconvenient for the patient. Patient volunteers or staff without medical training can also perform these to reduce cost further.


References

  1. A Scourfield et al. The use of calcaneal stiffness index to screen for osteoporosis in HIV-infected individuals. 17th Annual BHIVA Conference, 6–8 April 2011, Bournemouth. Oral abstract O33.
  2. Triant VA et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499-3504.
  3. European AIDS Clinical Society (EACS). Guidelines: Prevention and Management of Non-infectious Co-morbidities in HIV. www.europeanaidsclinicalsociety.org/guidelinespdf/2_Non_Infectious_Co_Morbidities_in_HIV.pdf



This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement